Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: advances in surgical treatment of differentiated thyroid cancer

Qian SHI; Jugao FANG

doi:10.19401/j.cnki.1007-3639.2025.10.004

您当前的位置：

首页 >

文章列表页 >

Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: advances in surgical treatment of differentiated thyroid cancer

Specialist's Commentary | 更新时间：2025-12-31

- Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: advances in surgical treatment of differentiated thyroid cancer
- China Oncology Vol. 35, Issue 10, Pages: 929-934(2025)
- 作者机构：
  
  首都医科大学附属北京同仁医院耳鼻咽喉-头颈外科，北京 100730
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2025.10.004
  CLC： R736.1
- Received：26 September 2025，
  
  Revised：2025-10-24，
  
  Published：30 October 2025
- 稿件说明：
移动端阅览
Qian SHI, Jugao FANG. Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: advances in surgical treatment of differentiated thyroid cancer[J]. China Oncology, 2025, 35(10): 929-934.
DOI：

Qian SHI, Jugao FANG. Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: advances in surgical treatment of differentiated thyroid cancer[J]. China Oncology, 2025, 35(10): 929-934. DOI： 10.19401/j.cnki.1007-3639.2025.10.004.

摘要

《2025版美国甲状腺学会成人分化型甲状腺癌管理指南》（简称2025年版ATA指南）对于分化型甲状腺癌（differentiated thyroid cancer，DTC）的外科治疗总体的趋势是，低危组的患者手术范围更加趋于保守，中危组病例倾向采用个体化治疗；强调根据患者的病变范围、临床分期和肿瘤的特性、患者的偏好来选择治疗方案。在确定初步治疗目标时，与患者共同决策至关重要。对于Ⅵ区淋巴结的预防性清扫，也偏向保守。在推荐治疗方案时，必须酌情考虑患者的偏好。对于选择手术治疗的患者，首要目标是切除原发肿瘤以及转移淋巴结，手术切除的彻底性是决定患者预后的重要因素。手术治疗的主要目标是：① 降低疾病持续/复发和转移扩散的风险。② 最大限度地减少治疗相关并发症。一定要权衡手术的获益和风险，这些风险如永久性甲状旁腺功能低下所带来的负担和对患者的伤害可能超过甲状腺癌疾病本身。本文对2025年版ATA指南在外科治疗领域的内容更新和进展要点予以梳理，以期为甲状腺癌外科医师提供参考。

Abstract

Regarding the surgical treatment of differentiated thyroid cancer (DTC) in the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer (abbreviation ATA guideline)

the overall trend is that for patients in the low-risk group

the surgical scope tends to be more conservative

while for cases in the intermediate-risk group

more individualized treatment is adopted. It emphasizes that the treatment plan should be selected based on the extent of disease

clinical stage

tumor characteristics

and patient preferences. When determining initial treatment goals

shared decision-making with the patient is crucial. When recommending treatment plans

patient preferences must be taken into account as appropriate. For patients who choose surgical treatment

the primary goal is to resect the primary tumor and metastatic lymph nodes. The completeness of surgical resection is an important factor determining prognosis. The main goals should be: reducing the risk of persistent/recurrent disease and metastatic spread

and minimizing treatment-related complications. It is essential to weigh the benefits and risks of surgery; for instance

the burden and harm to the patient caused by permanent hypoparathyroidism may outweigh the thyroid cancer itself. This article summarizes the important progress of the 2025 ATA guidelines in the field of surgery

in order to provide reference for thyroid cancer physicians.

关键词

Keywords

references

WANG X F , ZHENG X , ZHU J Q , et al . Impact of extent of surgery on long-term prognosis of follicular thyroid carcinoma without extrathyroidal extension and distant metastasis [J ] . World J Surg , 2022 , 46 ( 1 ): 104 - 111 . DOI: 10.1007/s00268-021-06337-4 http://doi.org/10.1007/s00268-021-06337-4 https://onlinelibrary.wiley.com/doi/10.1007/s00268-021-06337-4 https://onlinelibrary.wiley.com/doi/10.1007/s00268-021-06337-4

RINGEL M D , SOSA J A , BALOCH Z , et al . 2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer [J ] . Thyroid , 2025 , 35 ( 8 ): 841 - 985 . DOI: 10.1177/10507256251363120 http://doi.org/10.1177/10507256251363120 https://www.liebertpub.com/doi/10.1177/10507256251363120 https://www.liebertpub.com/doi/10.1177/10507256251363120

RODRIGUEZ SCHAAP P M , BOTTI M , OTTEN R H J , et al . Hemithyroidectomy versus total thyroidectomy for well differentiated T1-2 N0 thyroid cancer: systematic review and meta-analysis [J ] . BJS Open , 2020 , 4 ( 6 ): 987 - 994 . DOI: 10.1002/bjs5.50359 http://doi.org/10.1002/bjs5.50359 https://academic.oup.com/bjsopen/article/4/6/987/6136145 https://academic.oup.com/bjsopen/article/4/6/987/6136145

TAN M P , AGARWAL G , REEVE T S , et al . Impact of timing on completion thyroidectomy for thyroid cancer [J ] . Br J Surg , 2002 , 89 ( 6 ): 802 - 804 . DOI: 10.1046/j.1365-2168.2002.02068.x http://doi.org/10.1046/j.1365-2168.2002.02068.x https://academic.oup.com/bjs/article/89/6/802/6144037 https://academic.oup.com/bjs/article/89/6/802/6144037

TUTTLE R M . Distinguishing remnant ablation from adjuvant treatment in differentiated thyroid cancer [J ] . Lancet Diabetes Endocrinol , 2019 , 7 ( 1 ): 7 - 8 . DOI: 10.1016/S2213-8587(18)30335-8 http://doi.org/10.1016/S2213-8587(18)30335-8 https://linkinghub.elsevier.com/retrieve/pii/S2213858718303358 https://linkinghub.elsevier.com/retrieve/pii/S2213858718303358

ZIZIC M , FAQUIN W , STEPHEN A E , et al . Upper neck papillary thyroid cancer (UPTC): a new proposed term for the composite of thyroglossal duct cyst-associated papillary thyroid cancer, pyramidal lobe papillary thyroid cancer, and Delphian node papillary thyroid cancer metastasis [J ] . Laryngoscope , 2016 , 126 ( 7 ): 1709 - 1714 . DOI: 10.1002/lary.25824 http://doi.org/10.1002/lary.25824 https://onlinelibrary.wiley.com/doi/10.1002/lary.25824 https://onlinelibrary.wiley.com/doi/10.1002/lary.25824

WEI S Z , LIVOLSI V A , BALOCH Z W . Pathology of thyroglossal duct: an institutional experience [J ] . Endocr Pathol , 2015 , 26 ( 1 ): 75 - 79 . DOI: 10.1007/s12022-015-9354-y http://doi.org/10.1007/s12022-015-9354-y

TAN H L , HUANG B Q , LI G Y , et al . A prediction model for contralateral central neck lymph node metastases in unilateral papillary thyroid cancer [J ] . Int J Endocrinol , 2021 , 2021 : 6621067 .

CHANDRASEKHAR S S , RANDOLPH GW , SEIDMAN M D , et al . American Academy of Otolaryngology-Head and Neck Surgery [J ] . Clinical Otolaryngol Head Neck Surg , 2013 , 148 ( 6 Suppl ): S1 - S37 .

LEONARD-MURALI S , IVANICS T , NASSER H , et al . Intraoperative nerve monitoring in thyroidectomies for malignancy: Does it matter [J ] . Am Surg , 2022 , 88 ( 6 ): 1187 - 1194 .

KIM M R , PARK Y J , PARK B W , et al . Can voice pitch be preserved in patients after transoral endoscopic thyroidectomy vestibular approach [J ] . J Clin Med , 2020 , 9 ( 9 ): 2777 . DOI: 10.3390/jcm9092777 http://doi.org/10.3390/jcm9092777 https://www.mdpi.com/2077-0383/9/9/2777 https://www.mdpi.com/2077-0383/9/9/2777

IWATA A J , LIDDY W , BARCZYŃSKI M , et al . Superior laryngeal nerve signal attenuation influences voice outcomes in thyroid surgery [J ] . Laryngoscope , 2021 , 131 ( 6 ): 1436 - 1442 . DOI: 10.1002/lary.v131.6 http://doi.org/10.1002/lary.v131.6 https://onlinelibrary.wiley.com/toc/15314995/131/6 https://onlinelibrary.wiley.com/toc/15314995/131/6

LANG B H , SHEK T W H , CHAN A O , et al . Significance of size of persistent/recurrent central nodal disease on surgical morbidity and response to therapy in reoperative neck dissection for papillary thyroid carcinoma [J ] . Thyroid , 2017 , 27 ( 1 ): 67 - 73 . DOI: 10.1089/thy.2016.0337 http://doi.org/10.1089/thy.2016.0337 https://www.liebertpub.com/doi/10.1089/thy.2016.0337 https://www.liebertpub.com/doi/10.1089/thy.2016.0337

ITO Y , HIGASHIYAMA T , TAKAMURA Y , et al . Prognosis of patients with papillary thyroid carcinoma showing postoperative recurrence to the central neck [J ] . World J Surg , 2011 , 35 ( 4 ): 2014 .

LAMARTINA L , BORGET I , MIRGHANI H , et al . Surgery for neck recurrence of differentiated thyroid cancer: outcomes and risk factors [J ] . J Clin Endocrinol Metab , 2017 , 102 ( 3 ): 1020 - 1031 . DOI: 10.1210/jc.2016-3284 http://doi.org/10.1210/jc.2016-3284

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Important research progress in clinical practice for early breast cancer in 2024

Survival and cause-of-death analysis of 55 thousand thyroid cancer cases in China from a large single institution hospital-based cancer registry database

Current status and prospect of diagnosis and treatment of bone metastasis of thyroid cancer

Research progress in epidemiology and risk factors of thyroid cancer

Important research progress in clinical practice for early breast cancer in 2023

Related Author

Xing LI

Ziqi PENG

Xinmiao YU

Feng JIN

Jie SHEN

Wanlin LIU

Zezhou WANG

Sibo MU

Related Institution

Department of Breast Surgery, the First Affiliated Hospital of China Medical University

Shanghai Engineering Research Center of Artificial Intelligence Technology for Tumor Diseases

School of Public Health, Fudan University

Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰